Hemo-oncology newbie Bayer gears up for copanlisib launch

After winning a May priority review from the FDA, Bayer should be hearing back on an approval for lymphoma prospect copanlisib sooner rather than later. And as the company ventures into the blood canc…
Read the full story: FiercePharma: Pharma